Resources
About Us
Meticulous Research®—a leading market research company, published a research report titled, ‘CAR T-cell Therapy Market by Brand (Abecma [idecabtagene vicleucel], Breyanzi [lisocabtagene maraleucel], Yescarta [axicabtagene ciloleucel]), Target Antigen (CD, BCMA, HER2), Indication (Lymphoma, ALL, AML, Multiple Myeloma) - Global Forecast to 2030.'
According to this latest publication from Meticulous Research®, the CAR T-cell therapy market is projected to reach $51.6 billion by 2030, at a CAGR of 43.3% from 2024 to 2030. The growth of this market is driven by increasing cancer prevalence, a rise in awareness regarding CAR T-cell therapy, and increasing R&D activities and clinical trials. However, the complex manufacturing process and adverse effects of the therapy may restrain the growth of this market. Additionally, a high scope in emerging economies, innovation in CAR T-cell therapies and manufacturing processes are creating opportunities for market growth. Moreover, the high treatment cost of therapy and the lack of skilled professionals are challenging factors for the market.
Developments in Cell Therapies to Offer Significant Opportunities for the CAR T-cell Therapy Market Growth
Consistent developments in CAR T-cell therapy at various stages will positively impact its efficacy. Some of these developments include allogeneic CAR T-cell procedures. This procedure avoids the issues with autologous CAR T-cells in harvesting, product variability, long vein-to-vein time, and T-cell dysfunction. This treatment will help to expand the patient category, such as those with low T-cell levels, harvest failures, or who need treatment before autologous CAR T-cells can be manufactured. Another major development is in the viral-vector capacity. The viral-vector capacity constraint and a limited number of third-party suppliers lead to the in-house production of these viral vectors. Also, the lenti or adeno-associated-virus-based approaches are time-consuming and inefficient. Hence, the need for efficient gene-transfer tools enables rapid modification of T-cells with CARs and additional modifications such as removing donor T-cell receptors, adding on-off switches that can turn off the CAR T to prevent toxicity, and secreted factors. These advanced gene-transfer tools may allow the testing of multiple modifications leading to more effective therapy processes. Moreover, high-quality assays, process innovations including cloud-based data transfer, and tracking and validating each step of manufacturing contribute to the increased demand for CAR T-Cell therapy in coming years.
The CAR T-cell therapy market is segmented by drug type {Abecma [idecabtagene vicleucel], Breyanzi [lisocabtagene maraleucel], Kymriah [tisagenlecleucel], Tecartus [brexucabtagene autoleucel], Yescarta [axicabtagene ciloleucel], and Carvykti [ciltacabtagene autoleucel]}, Target Antigen (CD, BCMA, HER2, Other Target Antigens), indication (lymphoma, acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, multiple myeloma, acute myeloid leukemia, other indications), and geography. The study also evaluates industry competitors and analyzes the regional and country-level markets.
Based on drug type, in 2024, the Yescarta (axicabtagene ciloleucel) segment is expected to account for the largest share of the CAR T-cell therapy market. The axicabtagene ciloleucel is used to treat B-cell lymphoma in adults. It helps overcome the body's immune system's weaknesses in cancer elimination, such as potentially poor T-cell function and inadequate amounts of tumor-specific T-cells, contributing to the large market share of this segment.
Based on target antigen, in 2024, the CD target antigen segment is expected to account for the largest share of the CAR T-cell therapy market. CD antigens are commonly found as surface antigens in various cancer cases. Hence, the therapy developed was particularly against CD antigens, contributing to the large market share of this segment.
Based on indication, in 2024, the lymphoma segment is expected to account for the largest share of the CAR T-Cell therapy market. The large market share of this segment is attributed to the increased number of lymphoma patients adopting CAR T-cell therapy as their treatment over others due to its effectiveness and positive results.
Geographic Review
This research report analyzes major geographies and provides a comprehensive analysis of North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), Latin America, and the Middle East & Africa. In 2024, North America is expected to account for the largest share of the CAR T-cell therapy market, followed by Europe and Asia-Pacific. Advanced healthcare infrastructure in the U.S. and Canada, the high adoption of advanced technologies, highly skilled professionals available for performing cancer treatment research studies and clinical studies, and the growing number of approvals boost the growth of this market in North America.
Key Players
The key players operating in the CAR T-cell therapy market are Novartis AG (Switzerland), bluebird bio, Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Caribou Biosciences, Inc. (U.S.), Cartesian Therapeutics, Inc. (U.S.), Pfizer Inc. (U.S.), Cellectis S.A. (France), Celyad Oncology SA (Belgium), Gilead Sciences, Inc. (U.S.), Intellia Therapeutics, Inc. (U.S.), Merck & Co., Inc. (U.S.), Amgen Inc. (U.S.), Inovio Pharmaceuticals, Inc. (U.S.), and OncoTherapy Science, Inc. (Japan).
Download Sample Report Here : https://www.meticulousresearch.com/download-sample-report/cp_id=5508
Key questions answered in the report-
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
India VNA & PACS Market to Reach $341.6 Million by 2031
Read MoreChina Microarray Market to Be Worth $910.4 Million by 2031
Read MoreChina Neurogenomics Market to Reach $562.1 Million by 2031
Read MoreELISA Market to be Worth $32.69 Billion by 2031
Read MoreDNA Sequencing Market to be Worth $21.30 Billion by 2031
Read MoreOral Care Market to be Worth $58.99 Billion by 2031
Read MoreSpirometer Market to be Worth $1.80 Billion by 2031
Read MorePet Care Market to be Worth $287.96 Billion by 2031
Read MoreRegenerative Medicine Market to be Worth $37.27 Billion by 2031
Read MoreHemostats Market to be Worth $5.32 Billion by 2031
Read MoreBioreactors Market to be Worth $39.96 Billion by 2031
Read MoreProtein Assays Market to be Worth $4.36 Billion by 2031
Read MoreVeterinary API Market to Reach $15.84 Billion by 2031
Read MoreAsia-Pacific NGS Automation Market to be Worth $371 Million by 2031
Read MoreLatin America NGS Market to be Worth $765.2 Million by 2031
Read MoreBiochemical Reagents Market to be Worth $39.61 Billion by 2031
Read MoreMicroarray Kits Market to be Worth $2.51 Billion by 2031
Read MoreAntibody Production Market to Reach $58.35 Billion by 2031
Read MoreMiddle East IVD Market to be Worth $2.15 Billion by 2031
Read MoreSpatial Genomics Market to be Worth $3.23 Billion by 2031
Read MoreAsia-Pacific IVD Market to be Worth $36.02 Billion by 2031
Read MoreEurope NGS Market to be Worth $6.40 Billion by 2030
Read MoreLab Automation Market to be Worth $11.31 Billion by 2031
Read MoreBioinformatics Market to Reach $31.71 Billion by 2031
Read MoreEurope IVD Market to be Worth $39.77 Billion by 2030
Read MoreSequencing Kits Market to be Worth $25.29 Billion by 2031
Read MoreVeterinary API Market to Reach $15.84 Billion by 2031
Read MoreSample Preparation Market to be Worth $12.77 Billion by 2031
Read MoreSurgical Robots Market Worth $25.47 Billion by 2030
Read MoreMedical Coatings Market Worth $3.32 Billion by 2030
Read MoreLiquid Handling Systems Market Worth $6.99 Billion by 2029
Read MoreElectrosurgery Market to be Worth $8.99 Billion by 2031
Read MoreRadiation Dose Management Market Worth $749.1 Million by 2029
Read MoreMolecular Diagnostics Market Worth $46.69 Billion by 2030
Read MoreNewborn Screening Market to be Worth $2.69 Billion by 2031
Read MorePharmacogenomics Market to be Worth $19.5 Billion by 2031
Read MoreDental Practice Management Software Market Worth $ 3.11 Billion by 2029
Read MoreNepal IVD Market Worth $62.7 Million by 2029
Read MorePharmaceutical Contract Packaging Market Worth $42.03 Billion by 2029
Read MoreIndonesia IVD Market Worth $1.11 Billion by 2029
Read MoreMedical Waste Management Market Worth $17.02 billion by 2030
Read MoreEmpty Capsules Market Worth $4.47 Billion by 2029
Read MoreClear Aligners Market to be worth $18.8 Billion by 2030
Read MoreHLA Typing Market Worth $1.9 Billion by 2029
Read MoreReal-world Data Market Worth $1.66 billion by 2029
Read MoreTrack and Trace Solutions Market Worth $27.27 billion by 2029
Read MoreSurface Disinfectant Market Worth $9.52 Billion by 2029
Read MoreElectronic Lab Notebook Market Worth $787.7 million by 2029
Read MoreRapid Diagnostics Market to be Worth $22.65 Billion By 2031
Read MorePlasma Therapy Market Worth $882.5 Million by 2028
Read MorePeripheral Vascular Devices Market Worth $12.02 Billion by 2028
Read MoreBiomaterials Market to Reach 128.7 Billion USD by 2023
Read MoreVaccine Storage Equipment Market Worth $1.83 billion by 2027
Read MorePlasma Fractionation Market Worth $46.9 Billion by 2029
Read MoreHome Healthcare Market to be Worth $514.5 Billion by 2030
Read MoreCardiac Pacemaker Devices Market Worth $4.34 Billion by 2028
Read MoreEuropean Laboratory Informatics Market Worth $1,084.3 Million By 2024
Read MoreCompetent Cells Market Worth 2,318.6 Million USD By 2023
Read MoreCancer Immunotherapy Market to be Worth $267.2 Billion by 2030
Read MoreMultimodal Imaging Market Worth $1.6 Billion By 2024
Read MorePulse Lavage Market to be Worth $661.1 Million by 2030
Read MoreMedical Cooling Systems Market Worth $2.8 Billion By 2024
Read MoreTissue Diagnostics Market Worth $8.52 Billion by 2029
Read MoreEndoscopy Equipment Market Worth $59.8 Billion by 2029
Read MoreAfrican Forensic DNA Testing Market Worth $136.3 Million by 2025
Read MoreClinical Trial Supplies Market to be Worth $5.59 Billion by 2031
Read MoreInfection Control Market Worth $58.2 Billion by 2027
Read MoreSleep Apnea Devices Market Worth $12.9 billion by 2027
Read MoreMedical 3D Printing Market To Reach $983.2 Million By 2020
Read MoreGenomics Market to be Worth $70.52 Billion by 2031
Read MoreAnalytical Standards Market Worth $2.66 Billion By 2027
Read MoreTelehealth Market Worth $539.73 Billion by 2029
Read MoreCell Culture Market Worth $48.63 Billion by 2029
Read MoreAntimicrobial Coatings Market to be Worth $12.41 Billion by 2031
Read MoreFlow Cytometry Market Worth $6.4 Billion by 2027
Read MoreMedical Aesthetics Market Worth $29.43 billion by 2029
Read MoreOligonucleotide Synthesis Market Worth $3.9 Billion by 2025
Read MoreIn Vitro Diagnostics Market to be Worth $116.28 Billion by 2031
Read MoreDental Implants Market Worth $6.52 Billion by 2029
Read MoreActive Implantable Devices Market Worth 24.02 Billion USD By 2022
Read MoreVentilators Market to be Worth $13.23 Billion by 2031
Read MoreDialysis Market to be Worth $36.6 Billion by 2031
Read MorePlasmapheresis Market to be Worth $2.55 Billion by 2030
Read MoreDiabetes Care Devices Market Worth $31.9 Billion by 2028
Read MoreClinical Genomics Market Worth 879.0 Million USD By 2023
Read MoreIVD Quality Control Market to be Worth $2.28 Billion by 2031
Read MoreLaboratory Informatics Market Worth $6.1 Billion by 2030
Read MoreChromatography Data Systems Market to be Worth $1.7 billion by 2030
Read MoreBone Growth Stimulators Market Worth $1.94 Billion by 2030
Read MoreDigital Diabetes Market worth $12.03 billion by 2025
Read MoreTrocars Market Worth $968.5 Million by 2024
Read MoreHealthcare Virtual Assistant Market Worth $1.76 Billion By 2025
Read MoreEurope Hospital Beds Market to be Worth $2.09 Billion by 2030
Read MoreImmunoassay Market Worth $46.49 Billion by 2028
Read MoreHospital Beds Market Worth $ 6.66 Billion by 2030
Read MoreUrinalysis Market Worth $2.19 billion by 2027
Read MoreMedical Image Management Market Worth $7.22 billion by 2030
Read MoreBreast Imaging Market Worth $7.08 Billion by 2027
Read MoreVNA & PACS Market to be Worth $6.50 Billion by 2031
Read More